Arcellx Q3 2023 Earnings Report
Key Takeaways
Arcellx reported collaboration revenue of $15.0 million for Q3 2023, driven by the Kite Pharma agreement. The company's cash, cash equivalents, and marketable securities totaled $482.7 million as of September 30, 2023, expected to fund operations into 2026. Net loss for the quarter was $39.3 million.
Announced oral presentation at ASH in December, highlighting CART-ddBCMA trial data with median follow-up of 22 months.
CART-ddBCMA continues to be well-tolerated with no observed delayed neurotoxicities or parkinsonian symptoms.
Resumed enrollment in iMMagine-1 study, advancing the program towards commercial availability.
New clinical data from CART-ddBCMA Phase 1 trial will be presented at the ASH Annual Meeting.
Arcellx
Arcellx
Forward Guidance
Arcellx anticipates that its cash, cash equivalents, and marketable securities will fund its operations into 2026.